Hologic (NASDAQ:HOLX) had its price objective upped by research analysts at Morgan Stanley from $55.00 to $68.00 in a research note issued to investors on Friday, BenzingaRatingsTable reports. The brokerage currently has an “equal weight” rating on the medical equipment provider’s stock. Morgan Stanley’s price target would suggest a potential downside of 2.55% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $84.00 price objective (up previously from $63.00) on shares of Hologic in a report on Wednesday. Needham & Company LLC boosted their price objective on shares of Hologic from $64.00 to $78.00 and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Co raised their target price on Hologic from $63.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday. Zacks Investment Research lowered Hologic from a “hold” rating to a “sell” rating and set a $52.00 price target for the company. in a report on Tuesday, April 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Monday, July 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Hologic currently has an average rating of “Buy” and a consensus target price of $65.38.

HOLX stock opened at $69.78 on Friday. The company has a market cap of $18.07 billion, a P/E ratio of 28.25, a price-to-earnings-growth ratio of 3.69 and a beta of 1.47. Hologic has a 1 year low of $26.49 and a 1 year high of $70.35. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.47 and a quick ratio of 1.04. The stock’s fifty day moving average price is $57.42 and its 200-day moving average price is $50.06.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.37. The company had revenue of $822.90 million during the quarter, compared to analysts’ expectations of $622.96 million. Hologic had a return on equity of 31.40% and a net margin of 20.03%. Hologic’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 earnings per share. As a group, analysts expect that Hologic will post 2.42 earnings per share for the current year.

In other news, insider Peter J. Valenti III sold 10,493 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $54.07, for a total value of $567,356.51. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Stephen P. Macmillan sold 190,996 shares of the business’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $50.97, for a total transaction of $9,735,066.12. The disclosure for this sale can be found here. Insiders sold a total of 243,932 shares of company stock valued at $12,507,250 over the last 90 days. 1.00% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in shares of Hologic by 1.2% in the first quarter. State Street Corp now owns 11,584,851 shares of the medical equipment provider’s stock worth $406,628,000 after buying an additional 137,837 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Hologic by 11.3% in the first quarter. Nuveen Asset Management LLC now owns 3,548,837 shares of the medical equipment provider’s stock valued at $124,564,000 after purchasing an additional 359,054 shares in the last quarter. Norges Bank bought a new stake in Hologic in the fourth quarter worth $153,506,000. Legal & General Group Plc lifted its position in Hologic by 3.2% during the first quarter. Legal & General Group Plc now owns 2,081,642 shares of the medical equipment provider’s stock valued at $73,222,000 after purchasing an additional 64,794 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Hologic by 68.4% in the 1st quarter. AQR Capital Management LLC now owns 1,689,040 shares of the medical equipment provider’s stock valued at $59,285,000 after acquiring an additional 686,101 shares during the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: What is a good dividend yield?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.